Clinical Conversations: The Choice of Adrenaline Injectors – A Practical Approach for GPs | Part One

Maria Said AM

writer

Maria Said AM

Registered Nurse; CEO of Allergy & Anaphylaxis Australia; Associate member of the Australasian Society of Clinical Immunology and Allergy

Maria Said AM

 

Two adrenalin injectors are now available and this allows the patients a choice, but GPs need to be familiar with both devices. RN Maria Said, the CEO of Allergy and Anaphylaxis Australia, discusses the devices and issues concerning the prescription and use of adrenaline injectors. This is a three-part article.

This is part one of a three part series.
Read part two
Read part three

Practice points

• The Epipen® has two strengths, a 150 ug dose for 7.5 kg to 20 kg and a 300 ug dose for over 20 kg according to ASCIA guidelines.
• The Anapen®has three strengths, 150 ug dose for 10 kg to 20 kg, a 300ug dose for 20 kg to 50 kg and the ASCIA prescription guidelines say that the 500 ug dose of Anapen® is for anyone weighing 50 kg and over.
• Anyone weighing more than 50 kg can be prescribed either the 300 ug dose of Epipen® or the 500 ug dose of Anapen®.
• Both the 150 ug dose of Epipen® and Anapen® have green labelling, both the 300 ug dose of Epipen® and 300ug dose of Anapen® have a bright yellow labelling and as there is no equivalent of 500 ug for Epipen®, the 500 ug Anapen® colouring is magenta.
• After use, the Anapen® will have the needle exposed so care is needed with where it is put.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Debbie Rigby

A/Prof Debbie Rigby

Why Inhaler Device Design and Technique Matters

Dr Philip Tong

Dr Philip Tong

Facial Rashes Case Studies – Practical Guide to Assessment and Management

Dr Rupert Hinds

Dr Rupert Hinds

Abdominal Pain in Children – Practical Approach in GP

Prof Roger Chen

Prof Roger Chen

Practical Guide to Improving Control of T2D

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Maria Said AM

writer

Maria Said AM

Registered Nurse; CEO of Allergy & Anaphylaxis Australia; Associate member of the Australasian Society of Clinical Immunology and Allergy

Test your knowledge

Recent articles

Latest GP poll

In the last twelve months, how many adverse outcomes have you encountered arising from pharmacy prescribing?

None

0%

1-2

0%

Three or more

0%

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Upcoming Healthed Webcast

Tune in for "Facial rashes case studies - Practical guide to assessment and management" lecture

Tuesday 9th June, 7pm - 9pm AEST

Speaker

Dr Philip Tong

Consultant Dermatologist; Founder, DermScreen, Dermatology Junction; Visiting Medical Officer, St Vincent’s Hospital Sydney

What does it mean when a facial red rash does not respond to topical steroids and gets worse with the treatment? Dermatologist Dr Philip Tong presents a series of cases with this scenario.